IngredientesXylooligosaccharides (abbreviated XOS) are classified as non-digestible prebiotic dietary fibers belonging to the broader family of functional oligosaccharides. XOS are sugar oligomers composed of β-d-xylopyranosyl (xylose) units bound through β(1→4)-xylosidic linkages. Their C5 sugar architecture distinguishes them chemically from the majority of other established prebiotics: their C5 structure is fundamentally different from other prebiotics, which are based upon C6 sugars.
Generally, XOS are mixtures of sugar oligomers made up of xylose units linked via β-(1→4) xylosidic bonds and they can contain several functional groups — for example arabinosyl residues, acetyl groups, uronic acids, or phenolics — forming branched structures. Depending on the biomass source and the production process, the structures of XOS can present different degrees of polymerization (DP), patterns of substitution of the main chain, and types of linkages. In particular, the DP can vary from 2 to 10 xylose molecules.
The named individual oligomers within the XOS family progress with chain length: XOS are sugar oligomers comprised of xylose units through β-(1–4)-xylosidic linkages, specifically xylobiose (2 monomers), xylotriose (3 monomers), xylotetraose (4 monomers), xylopentose (5 monomers), and xylohexose (6 monomers). Commercially available preparations typically contain a mixture of these, with XOS constituted as β-1,4-xylooligosaccharides with a DP of 2–6, mostly composed of non-digestible xylose-based disaccharide (xylobiose, approximately 35%) and approximately 60% total fiber comprising non-digestible oligomers with DP of 3–6.
The FDA-facing regulatory description characterizes the material as follows: XOS (1,4-β-xylooligosaccharides) presents as an off-white to tan powder with a slightly sweet taste, and is described as a non-digestible polymer of D-xylopyranosyl (xylose) residues linked by β-(1→4) glycosidic bonds.
XOS are naturally present in bamboo shoots, fruits, vegetables, milk, and honey. However, concentrations in these natural foods are low. By nature, XOS is present in vegetables, fruits, honey, milk, and bamboo shoots in limited quantity, making it economically unsuitable for large-scale production and purification.
The primary precursor molecule for commercial XOS production is xylan, which is the hemicellulosic polysaccharide of plant cell walls. Xylan is the most abundant and complex type of glycan present in cell walls of various cereal grains consumed by humans, including wheat, rye, and oat. It consists mainly of a linear backbone of β-1,4-D-xylopyranoside units that are often modified with 4-O-methyl-glucuronyl, acetyl, feruloyl, and α-L-arabinofuranosyl residues. In hardwoods used as XOS feedstocks, xylan in hardwoods such as birch (Betula spp.) and eucalyptus (Eucalyptus spp.) constitutes 15–30% of the dry biomass, making these trees significant natural reservoirs for XOS precursors.
Because natural concentrations of XOS in foods are insufficient for industrial supply, chemical synthesis or enzymatic hydrolysis of a suitable substrate such as xylan to produce XOS is the most preferred process on an industrial scale. Common lignocellulosic feedstocks include corn cob, wheat and rice straws, tobacco stalks, sugarcane bagasse, and brewers' spent grains, processed via chemical, physical, and enzymatic methods. These processes vary in yield, purity, specificity, cost, and environmental impact, with enzymatic hydrolysis being faster and more eco-friendly than chemical and physical hydrolyses.
One specific production pathway documented in an FDA GRAS notification involves sugarcane: XOS derived from food-grade high-fiber hybrid sugarcane (Saccharum species), where the harvested raw sugarcane is shredded, then washed with water and pressed to recover fiber solids. Commercially, XOS is available in powder or tablet format as a standalone ingredient or combined with probiotics or other prebiotics. Its physical stability is notable: XOS is stable over a wide range of pH (2.5–8.0), an advantage compared with many other prebiotic oligosaccharides. This acid stability means XOS survives the acidic environment of the stomach and upper gastrointestinal tract.
XOS as an isolated or concentrated supplement has no extended traditional use in the sense of herbal medicine or classical pharmacopeias. The molecule itself occurs naturally in foods that have been dietary staples across multiple cultures for centuries, particularly in East Asia. Cultures that consumed high amounts of root vegetables, whole grains, legumes, and fibrous plant parts — such as the Japanese diet rich in bamboo shoots, traditional Mediterranean diets, or indigenous diets with wild plant fibers — experienced many of the same benefits that XOS now deliver in concentrated form, by naturally providing a favorable environment for beneficial gut bacteria.
The traditional use of bamboo shoots — one of the richest natural food sources of xylan and XOS precursors — is documented across numerous Asian cultures. In northern Thailand, for example, Naw Mai Dong is an ethnic fermented bamboo shoot product popular in the upper northern region, where xylan, a component of hemicellulose found in bamboo shoots, serves as raw material utilized in xylooligosaccharide production. To produce Naw Mai Dong, bamboo shoots are sliced and pickled in bottles or jars containing water rinsed from rice crops.
As a modern supplement ingredient, XOS has a definable commercial origin: xylooligosaccharides have been commercially available since the 1980s, originally produced by Suntory in Japan. They have more recently become more widely available commercially, as technologies have advanced and production costs have fallen. The Japanese market pioneered the incorporation of XOS into foods, and today a significant number of companies use XOS in food products. Japan has also assigned XOS a specific regulatory category: Japan recognizes XOS as a Food for Specified Health Uses (FOSHU), a classification that permits health claims on products containing XOS, subject to approval.
The fundamental mechanism underlying all XOS activity is their resistance to mammalian digestive enzymes. XOS are composed of β-D-xylopyranose units linked by β-glycosidic bonds and are resistant to mammalian digestion but fermentable by beneficial gut bacteria. XOS produced are non-digestible carbohydrates being stable under stomach pH and digestive enzymes, so they can be easily delivered to the intestine in native form, thus stimulating the growth of probiotics. This property is the cornerstone of all downstream biological effects.
Upon reaching the colon, XOS are selectively fermented by specific members of the gut microbiota. In the body, XOS is fermented by Bifidobacterium spp. and Lactobacillus spp. in the microbiota, consequently increasing their relative abundance within the gastrointestinal tract and producing fecal short-chain fatty acids (SCFAs). The capacity of gut bacteria to degrade XOS is linked to specialized enzyme systems. Bacteroides and Roseburia species have been shown to produce endoxylanases for breaking down the backbone of this complex polysaccharide; in Bacteroides, the xylan degradation machinery is encoded by a polysaccharide utilisation locus, encompassing outer membrane enzymes that cleave long glycan chains into oligosaccharides.
The principal measurable outcome of XOS fermentation is the production of SCFAs, primarily acetate, propionate, and butyrate. XOS augments microbiota-derived metabolites, mainly butyrate, propionate, and secondary bile acids, which strengthen the gut barrier and regulate gut immunity through activating host G-protein coupled receptors 109a or inhibiting histone deacetylases. These SCFAs exert multiple systemic effects: SCFAs regulate immunity and suppress or promote inflammatory responses in the gut and other organs; they play an important role in the regulation of innate and adaptive immunity mediated by a variety of mechanisms, including histone deacetylase (HDAC) inhibition, G-protein-coupled receptor (GPR) signaling, acetyl-CoA production, and metabolic integration.
Butyrate in particular has specific roles in gut barrier integrity: SCFAs promote the integrity and permeability of the gut barrier in different ways; these molecules, mainly butyrate, increase the concentration of tight junctions such as claudin-1, zonula occludens-1, and occludin through the upregulation of genes encoding for these proteins; butyrate is also able to strengthen the mucus layer of the gut epithelium by increasing the expression of Mucin 2.
Beyond SCFA production, animal research has described direct effects of XOS on intestinal barrier gene expression. XOS enhanced the mRNA expression levels of zonula occludens-1 (ZO-1), occludin, and claudin-1 in the small intestine, increased the strength of the intestinal barrier, and optimized the composition of the intestinal microbiota. In animal models of inflammation, the plasma levels of monocyte chemoattractant protein-1, tumor necrosis factor (TNF-α), and lipopolysaccharide decreased in XOS-treated animals; XOS treatment also decreased TNF-α mRNA expression and increased occludin mRNA expression in the rat colon.
In rodent studies, XOS has been shown to activate gene-level pathways involved in lipid metabolism. XOS intervention activated the AMP-activated protein kinase (AMPK) pathway to regulate fat synthesis, decomposition, and β-oxidation; upregulated the mRNA expression levels of carnitine palmitoyl transferase 1 (CPT-1), peroxisome proliferator-activated receptors α (PPAR-α), and cholesterol 7-alpha hydroxylase (CYP7A1); and downregulated the mRNA expression levels of acetyl-CoA carboxylase (ACC), CCAAT/enhancer-binding protein alpha (C/EBPα), and lipoprotein lipase (LPL).
XOS exhibits strong antioxidant and excellent antibacterial properties, and can be utilized by gut microbes to maintain the ecological balance of the intestinal tract. Butyrate specifically contributes to antioxidant defense: butyrate is involved in the modulation of oxidative stress, as it reduces H₂O₂-induced DNA damage, restoring the levels of antioxidant glutathione.
The most thoroughly investigated and consistently demonstrated effect of XOS is its bifidogenic prebiotic activity. Research results indicate that XOS enhance the growth of probiotics, having a bifidogenic effect, which stimulates the production of short-chain fatty acids (SCFAs), and suppress the proliferation of pathogens.
Human clinical evidence: A foundational double-blind, randomized, placebo-controlled study examined microbiota changes in healthy adults. Healthy adult subjects (n = 32) were recruited in a double-blind, randomized, placebo-controlled study. Subjects received 1.4 g XOS, 2.8 g XOS, or placebo in daily doses. The study consisted of a 2-week run-in, an 8-week intervention, and a 2-week washout phase. This study, documented by Finegold et al. (2014), showed a selective and dose-dependent increase in Bifidobacterium without a significant increase in Lactobacillus. Importantly, the dose of FOS required to significantly increase Bifidobacterium counts in the human gut is in the range of 10 to 20 grams, whereas XOS achieves comparable effects at a fraction of that dose.
A separate 6-week randomized, placebo-controlled trial with 20 healthy subjects examined XOS delivered in a food matrix. The study investigated the effects of XOS-enriched rice porridge consumption; twenty healthy subjects participated, in which 10 subjects received XOS-enriched rice porridge while the others received placebo rice porridge; fecal samples were collected at the end of weeks 0, 1, 3, 4, 6, and 7 for microorganism examination. The results showed that 6-week daily ingestion of the XOS-enriched rice porridge induced significant increases in fecal bacterial counts of Lactobacillus spp. and Bifidobacterium spp., as well as decreases in Clostridium perfringens, without changing the total anaerobic bacterial counts, compared to placebo.
An additional pilot study assessed XOS in healthy and prediabetic adults, finding that microbiota alterations occurred in both populations, suggesting the bifidogenic effect is not limited to healthy individuals. There are not many studies in humans about the effects of XOS consumption on gut microbiota, but the ones available have obtained promising results. Human clinical trials assessing the prebiotic potential of XOS collectively suggest positive effects on gut microbiota composition and certain systemic parameters; across two double-blind, randomized, placebo-controlled studies on healthy persons who consumed commercial corn cob XOS, the bifidogenic effect was consistently demonstrated.
Evidence strength: The bifidogenic prebiotic effect of XOS in humans is supported by multiple randomized controlled trials and is among the most consistently demonstrated actions of XOS. The evidence is moderately strong for this specific outcome, though the overall number of human trials remains limited compared to more established prebiotics like inulin and FOS.
Human clinical evidence: A randomized, double-blind, controlled trial directly evaluated XOS in functional constipation (FC). A randomized double-blind controlled trial was conducted in FC patients who were randomly divided into 6 groups and given a dietary supplement containing XOS at doses of 3, 5, or 10 g/day, FOS at doses of 10 and 20 g/day, or placebo at 5 g/day for one month; improvements in gastrointestinal function were assessed using the Bristol Stool Form Scale (BSFS), Cleveland Clinic Constipation Score (CCCS), and Quality of Life Scale for Patients with Constipation (PAC-QoL); 16S rRNA sequencing was used to assess changes in gut microbiota structure. The study demonstrated that XOS supplementation improved FC symptoms and was associated with targeted enrichment of Bifidobacterium in the gut.
An older study assessed 4 g/day XOS over 21 days in elderly patients: a study assessing the effects of a 4 g/day dose of XOS on the intestinal microbiota, gastrointestinal function, and nutritional parameters in elderly patients over a 21-day period concluded that XOS supplementation promoted intestinal health and showed no adverse effects on the elderly study population.
Evidence strength: Preliminary to moderate. Clinical trials demonstrate positive outcomes on bowel function and constipation symptoms, but the evidence base is still limited in trial number and scale. Larger, adequately powered trials are needed to confirm these findings.
Human clinical evidence: A small but well-designed randomized, double-blind clinical trial examined XOS effects in type 2 diabetes mellitus. The purpose of this study was to evaluate the effect of XOS on blood sugar, lipids, and oxidative status in type 2 diabetes mellitus; a total of 26 outpatient subjects with HbA1c levels between 7.0 and 10.0% and triglyceride <400 mg/dL were enrolled; subjects were supplemented with 4 g/day XOS (n=12) or a placebo (n=14) for 8 weeks in a randomized double-blind clinical design. XOS supplementation not only reduced glucose, HbA1c, and fructosamine concentrations, but also decreased the levels of total cholesterol, LDL cholesterol, oxidized LDL (ox-LDL), and apolipoprotein B.
A randomized, double-blind crossover study explored the impact of XOS on glycemic index (GI) in healthy adults. The objective was to investigate the effects of XOS-sugar mixtures on GI and blood glucose in human subjects; double-blind cross-over studies examined sucrose with 14% XOS powder (Xylo 14) and sucrose with 20% XOS powder (Xylo 20) on GI and postprandial glucose response. GIs of Xylo 14 and Xylo 20 were 60.0 ± 23.5 (medium GI range) and 54.3 ± 17.7 (low GI range), respectively; both preparations showed significantly lower area under the glucose curve (AUC) at every measured interval from 15 to 120 minutes.
Evidence strength: Preliminary. Human data on glycemic effects of XOS are encouraging but derive from small studies (n=26 or less for individual trials in patients with diabetes). Larger clinical trials are required to confirm these metabolic effects.
As described in the type 2 diabetes trial above, XOS supplementation decreased the levels of total cholesterol, LDL cholesterol, ox-LDL, and apolipoprotein B in addition to glycemic markers, suggesting a potential dual benefit on cardiometabolic risk. In animal models, XOS inhibited mouse weight gain, decreased the epididymal adipose index, and improved blood lipid levels including triglyceride (TG), total cholesterol (TC), and LDL-C levels; moreover, XOS reduced the activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage caused by the high-fat diet.
One human study additionally reported improved plasma lipid profiles in healthy adults alongside the bifidogenic effect: improvement in plasma lipids, modulation of markers of immune function, and increased participant-reported vitality and happiness were reported after XOS intake.
Evidence strength: Preliminary for humans; predominantly animal/in vitro for mechanistic lipid pathway effects. The human signal from the diabetes trial is the strongest clinical data point, but the small sample size limits conclusions. Animal data support mechanistic plausibility via AMPK and PPAR-α pathway modulation.
Recent animal research has investigated XOS in the context of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD). A study investigated the dose-dependent protective effects of XOS against MASLD in mice, where male C57BL/6 mice were fed either a low-fat diet, a high-fat diet, or HFD supplemented with low-dose XOS (0.38 g/kg) or high-dose XOS (1.0 g/kg) for 16 weeks; high-dose XOS, but not low-dose, significantly reduced serum ALT and triglycerides levels, alleviated hepatic steatosis, and improved the villus height-to-crypt depth ratio. The observation that low-dose XOS affects only a few taxa without systemic improvement underscores the need for adequate prebiotic dosing to achieve effective microbiota remodeling.
It was concluded that XOS regulated the intestinal barrier, changed the intestinal microecology, and played an important role in preventing hyperlipidemia through the unique anatomical advantages of the gut–liver axis.
Evidence strength: Preclinical only. No human clinical trials in hepatic steatosis or liver disease have been published to date. Animal findings are mechanistically interesting but cannot be directly extrapolated to humans.
Fermentation of XOS in the colon lowers luminal pH, which has downstream effects on mineral solubility and absorption. XOS fermentation in the colon produces short-chain fatty acids (primarily acetate, propionate, and butyrate), which lower colonic pH; this more acidic environment increases the solubility of calcium and magnesium salts, facilitating their passive absorption across the colonic mucosa.
Animal research has specifically tested bone outcomes. XOS intervention significantly decreased cecum pH and increased cecum wall weight in a dose-dependent manner; at the late growth stage, compared with 0% XOS, bone mineral density (BMD) and bone-breaking strength in 4% XOS were significantly higher; the bone crystallinity with 4% XOS was significantly enhanced compared to 0% XOS during later growth. The expression of transient receptor potential vanillin receptor 6 (TRPV6) and Na⁺/Ca²⁺ exchanger 1 (NCX1) in the duodenum were enhanced by XOS supplementation; XOS exerted a positive influence on bone properties by decreasing cecum pH, increasing cecum wall and villus structure, and upregulating the expression of related calcium transporters.
Evidence strength: Mechanistically plausible and supported by animal data; human clinical evidence on mineral absorption specifically with XOS remains limited. This area warrants dedicated human trials.
The relationship between XOS and immune function is mediated primarily through its effects on gut microbiota and SCFA production. In animal models, XOS confirmed positive effects on gut barrier enhancement via suppressing the expression of pro-inflammatory cytokines (IL-6 and IL-8); meanwhile, XOS increased beneficial microbes Lactobacillus and decreased potentially pathogenic bacteria. In rat models of obesity-induced inflammation, XOS treatment was associated with reductions in systemic inflammatory markers alongside microbiota restructuring.
Evidence strength: Largely preclinical (animal and in vitro). The immune-related effects reported in one human XOS study were secondary outcomes. Direct immunological endpoints have not been the primary focus of large human trials.
Animal studies report that XOS can counteract high-fat diet-induced weight gain and associated metabolic disruption. Dietary supplementations with 5% and 10% XOS could significantly slow down body weight gain and improve glucose intolerance; lipidomic analyses revealed an alteration in 31 metabolic molecules, in particular ceramide and diacylglycerol species in plasma; gut microbiota analysis showed that XOS changed the composition of gut microbiota, leading to an increase in the relative population of Bifidobacterium, Lachnospiraceae_NK4A136_group, and Roseburia.
Evidence strength: Primarily preclinical. Obesity-related outcomes in humans have not been the focus of dedicated RCTs with XOS. Animal data are consistent but cannot be directly extrapolated.
XOS is available in powder or tablet format as a standalone ingredient or combined with probiotics or other prebiotics. Reported dosages across clinical studies span a range from very low to moderate:
A key comparative advantage of XOS over other prebiotics is its effective dose: the dose of FOS required to significantly increase Bifidobacterium counts in the human gut is in the range of 10 to 20 grams, whereas XOS achieves bifidogenic effects at 1.4–2.8 g/day — roughly a 5- to 10-fold lower dose.
XOS has a favorable tolerability profile compared to other prebiotic fibers. XOS has remarkable stability and heat resistance under both acidic and alkaline conditions, so it can pass through the stomach and small intestine until the posterior intestinal stage, and can play a regulatory role at low-dose supplementation. In human studies, adverse gastrointestinal effects have not been prominent at the doses studied. The doses used in human trials (1.4–10 g/day) were generally well-tolerated, with no serious adverse events reported.
A 26-week sub-chronic oral toxicity study in Beagle dogs was conducted to establish safety parameters. Beagle dogs were administered XOS at doses of 0, 1250, 2500, and 5000 mg/kg/day by oral gavage for 26 weeks; a 4-week recovery period was added to observe delayed or reversible toxicity; measurements included body weight, food consumption, clinical observations, temperature, ECG, urinalysis, blood chemistry, hematology, organ weight, gross necropsy, and histopathological examination; except for transient diarrhea or vomiting, no treatment-related adverse effects were noted. This chronic toxicity study demonstrated that the no observed adverse effect level (NOAEL) of XOS is 2500 mg/kg body weight/day; based on body surface area (conversion factor of 0.54 for dogs to human), this corresponds to daily doses of 1350 mg/kg BW or 81–108 g XOS in human adults weighing 60–80 kg.
In the mid-dose groups, transitional diarrhea was observed in the initial 1–2 weeks; in the high-dose groups, diarrhea and/or vomiting were observed episodically over the duration of treatment; however, these disappeared after XOS was withdrawn in the recovery period.
XOS has obtained Generally Recognized as Safe (GRAS) status by the United States FDA and has been accepted as a safe novel food by the European Food Safety Authority (EFSA) after evaluating a XOS product enzymatically produced from corncob. In the EU, XOS is classified as a novel food under Regulation (EU) 2015/2283. Japan recognizes XOS as a Food for Specified Health Uses (FOSHU). The FDA's GRAS assessment is reflected in the regulatory filing: xylooligosaccharides derived from sugarcane are GRAS for use in foods.
The differences in microbial diversity, community composition, and metabolite profiles between high- and low-dose XOS suggest that insufficient substrate fails to reconfigure dysbiotic communities; potential underlying mechanisms may involve elevated substrate availability shifting the competitive balance toward primary XOS utilizers, thereby sustaining cross-feeding chains that produce SCFAs and indole derivatives at physiologically relevant levels. This dose-response relationship has practical implications: both under-dosing (insufficient prebiotic effect) and theoretical over-dosing (transient gastrointestinal symptoms) represent relevant considerations in supplement design.
At the effective dose range demonstrated in human studies, XOS appears to produce fewer gastrointestinal side effects than equivalent bifidogenic doses of FOS or GOS. In threshold studies evaluating symptomatic response to FOS, excessive flatus and borborygmi were recorded by about 10% of volunteers at 10 g/day FOS, and excessive flatus, borborygmi, and bloating by about 20–30% of volunteers at 20 g/day — the dose range needed for FOS to achieve bifidogenic effects comparable to what XOS achieves at 1.4–2.8 g/day.
A study in elderly patients using a 4 g/day dose over 21 days concluded that XOS supplementation promoted intestinal health and showed no adverse effects on the elderly study population. No significant drug interactions with XOS have been identified in the published literature reviewed, and no formal interaction studies have been conducted. Because XOS lowers colonic pH and modulates the gut microbiome, theoretical interactions with gut-microbiome-dependent drug metabolism or absorption are biologically plausible but have not been empirically documented in human studies.
Condiciones de salud que xilooligosacáridos puede ayudar a apoyar.
XOS exhibits measurable antioxidant activity in vitro and in animal models, including free radical scavenging capacity and modulation of antioxidant enzymes. In T2DM clinical subjects, XOS supplementation affected erythrocyte catalase activity. XOS combined with Lactobacillus plantarum has shown free radical scavenging in vitro.
Clinical trials show XOS can lower blood glucose and HbA1c in type 2 diabetic patients and reduce glycemic response in healthy adults. A randomized double-blind trial in 26 T2DM subjects found 4 g/day XOS for 8 weeks reduced glucose, HbA1c, and fructosamine. XOS added to sucrose significantly lowered the glycemic index in healthy adult volunteers.
Preclinical evidence shows XOS can improve bone formation parameters in rodent models. XOS was demonstrated to reduce systemic inflammation, increase trabecular thickness, reduce osteoclasts and active erosive surfaces, and restore mineral deposition and bone formation rates in male Wistar rats. Human clinical evidence is not yet established.
Human clinical data in T2DM patients show XOS (4 g/day, 8 weeks) significantly reduced total cholesterol, LDL cholesterol, oxidized LDL, and apolipoprotein B. Animal studies confirm XOS reduces total cholesterol and LDL while increasing HDL in high-fat-diet models, partly through AMPK pathway activation and increased bile acid conversion.
Multiple studies in animals and humans demonstrate that XOS reduces pro-inflammatory cytokines and inflammatory markers. XOS modulates gut microbiota to favor SCFA-producing bacteria, which dampen colonic and systemic inflammation. In rodents, XOS supplementation significantly counteracted high-fat-diet-induced inflammatory cytokine elevation.
In vitro fermentation studies with fecal samples from UC patients in remission show XOS significantly enriches Bifidobacterium and butyrate-producing Roseburia, bacteria known to reduce colitis severity. Animal models confirm XOS combined with Bifidobacterium infantis alleviates dextran sulfate sodium-induced colitis. Human interventional trials in active colitis remain limited.
Xylooligosaccharides (XOS) are prebiotic fibers with evidence for constipation improvement from a clinical RCT. A 4-week double-blind, placebo-controlled RCT in 250 adults with functional constipation (Tandfonline 2023) found XOS-containing formulations significantly improved Bristol Stool Scale scores vs. placebo (p<0.05), supporting their prebiotic and fiber mechanisms in bowel regulation.
Xylooligosaccharides (XOS) are oligosaccharides derived from xylan with documented prebiotic activity, selectively stimulating Bifidobacterium growth and SCFA production including butyrate. Multiple in vitro fermentation studies and human trials confirm their gut microbiota-modulating effects as an emerging prebiotic.
XOS demonstrates benefits in IBD-relevant models by improving gut barrier function, increasing tight junction protein expression, and enriching beneficial bacteria depleted in both Crohn's disease and ulcerative colitis. In vitro and animal studies are promising; direct human RCT data in IBD remain limited.
XOS has been shown in pre-diabetic subjects and animal models to support insulin sensitivity via gut microbiota modulation, SCFA-mediated GLP-1 stimulation, and reduction of LPS-driven insulin resistance. A clinical pilot trial showed a non-significant trend to reduce 2-hour OGTT insulin in pre-diabetic subjects. Animal data with XOS in gestational diabetes and T2DM models show more robust improvements.
XOS promotes gut barrier integrity by stimulating SCFA-producing bacteria that strengthen tight junction proteins (ZO-1, occludin, claudin-1). In high-fat-diet animal studies, XOS upregulated tight junction gene expression in the small intestine. The evidence is primarily preclinical with limited direct human clinical data on intestinal permeability.
XOS addresses multiple components of metabolic syndrome including elevated blood glucose, dyslipidemia, and systemic inflammation. Studies in obese high-fat-diet models show XOS reduces body weight, visceral fat, blood lipids, and inflammatory markers. Human data show improvements in T2DM-associated metabolic parameters at 4 g/day.
The same randomized clinical trial in T2DM patients showing cholesterol reduction with XOS also showed lipid improvements, and animal studies consistently demonstrate XOS reduces serum and hepatic triglycerides. High-dose XOS in a murine MASLD model significantly reduced serum triglyceride levels and hepatic steatosis.
Sistemas corporales que xilooligosacáridos puede ayudar a apoyar.
Volver